Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Progressive multiple sclerosis? 99 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 99 reports of Progressive multiple sclerosis have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.2% of all adverse event reports for NATALIZUMAB.

99
Reports of Progressive multiple sclerosis with NATALIZUMAB
0.2%
of all NATALIZUMAB reports
8
Deaths
39
Hospitalizations

How Dangerous Is Progressive multiple sclerosis From NATALIZUMAB?

Of the 99 reports, 8 (8.1%) resulted in death, 39 (39.4%) required hospitalization, and 3 (3.0%) were considered life-threatening.

Is Progressive multiple sclerosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 99 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Progressive multiple sclerosis?

DIMETHYL (110) INTERFERON BETA-1A (105) DALFAMPRIDINE (89) GLATIRAMER (77) FINGOLIMOD (73) OCRELIZUMAB (63) TERIFLUNOMIDE (48) OFATUMUMAB (26) OMEPRAZOLE (25) DULOXETINE (24)

Which NATALIZUMAB Alternatives Have Lower Progressive multiple sclerosis Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Progressive multiple sclerosis Reports All Drugs Causing Progressive multiple sclerosis NATALIZUMAB Demographics